-
1
-
-
35248830118
-
Colorectal cancer
-
Ballinger AB and Anggiansah C. Colorectal cancer. BMJ. 2007; 335(7622):715-718.
-
(2007)
BMJ
, vol.335
, Issue.7622
, pp. 715-718
-
-
Ballinger, A.B.1
Anggiansah, C.2
-
2
-
-
77949437015
-
Colorectal cancer
-
Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N. Colorectal cancer. Lancet. 2010; 375(9719):1030-1047.
-
(2010)
Lancet
, vol.375
, Issue.9719
, pp. 1030-1047
-
-
Cunningham, D.1
Atkin, W.2
Lenz, H.J.3
Lynch, H.T.4
Minsky, B.5
Nordlinger, B.6
Starling, N.7
-
3
-
-
77955273537
-
-
Accessed on Nov 12, 2013
-
Ferlay J, Shin H, Bray F, Forman D, Mathers C and Parkin D. GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide. Available at: http://globocan.iarc.fr. Accessed on Nov 12, 2013. 2008.
-
(2008)
GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide
-
-
Ferlay, J.1
Shin, H.2
Bray, F.3
Forman, D.4
Mathers, C.5
Parkin, D.6
-
4
-
-
2542615200
-
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
-
Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I and de Gramont A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350(23):2343-2351.
-
(2004)
N Engl J Med
, vol.350
, Issue.23
, pp. 2343-2351
-
-
Andre, T.1
Boni, C.2
Mounedji-Boudiaf, L.3
Navarro, M.4
Tabernero, J.5
Hickish, T.6
Topham, C.7
Zaninelli, M.8
Clingan, P.9
Bridgewater, J.10
Tabah-Fisch, I.11
de Gramont, A.12
-
5
-
-
67649472398
-
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
-
Baselga J and Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009; 9(7):463-475.
-
(2009)
Nat Rev Cancer
, vol.9
, Issue.7
, pp. 463-475
-
-
Baselga, J.1
Swain, S.M.2
-
6
-
-
33749316418
-
The epidermal growth factor receptor pathway: a model for targeted therapy
-
Scaltriti M and Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006; 12(18):5268-5272.
-
(2006)
Clin Cancer Res
, vol.12
, Issue.18
, pp. 5268-5272
-
-
Scaltriti, M.1
Baselga, J.2
-
7
-
-
10744230127
-
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors
-
Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW and Yokoyama S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell. 2003; 12(3):541-552.
-
(2003)
Mol Cell
, vol.12
, Issue.3
, pp. 541-552
-
-
Burgess, A.W.1
Cho, H.S.2
Eigenbrot, C.3
Ferguson, K.M.4
Garrett, T.P.5
Leahy, D.J.6
Lemmon, M.A.7
Sliwkowski, M.X.8
Ward, C.W.9
Yokoyama, S.10
-
8
-
-
79960084377
-
Anti-HER agents in gastric cancer: from bench to bedside
-
Fornaro L, Lucchesi M, Caparello C, Vasile E, Caponi S, Ginocchi L, Masi G and Falcone A. Anti-HER agents in gastric cancer: from bench to bedside. Nat Rev Gastroenterol Hepatol. 2011; 8(7):369-383.
-
(2011)
Nat Rev Gastroenterol Hepatol
, vol.8
, Issue.7
, pp. 369-383
-
-
Fornaro, L.1
Lucchesi, M.2
Caparello, C.3
Vasile, E.4
Caponi, S.5
Ginocchi, L.6
Masi, G.7
Falcone, A.8
-
9
-
-
79952233837
-
Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers
-
Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, Gonzalez-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, Pidaparthi S, Mukherjee A, Leitzel K, Kostler WJ, et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 2011; 71(5):1871-1882.
-
(2011)
Cancer Res
, vol.71
, Issue.5
, pp. 1871-1882
-
-
Ghosh, R.1
Narasanna, A.2
Wang, S.E.3
Liu, S.4
Chakrabarty, A.5
Balko, J.M.6
Gonzalez-Angulo, A.M.7
Mills, G.B.8
Penuel, E.9
Winslow, J.10
Sperinde, J.11
Dua, R.12
Pidaparthi, S.13
Mukherjee, A.14
Leitzel, K.15
Kostler, W.J.16
-
10
-
-
0042307325
-
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
-
Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, 3rd and Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A. 2003; 100(15):8933-8938.
-
(2003)
Proc Natl Acad Sci U S A
, vol.100
, Issue.15
, pp. 8933-8938
-
-
Holbro, T.1
Beerli, R.R.2
Maurer, F.3
Koziczak, M.4
Barbas III, C.F.5
Hynes, N.E.6
-
11
-
-
0028077047
-
Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product
-
Kim HH, Sierke SL and Koland JG. Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product. J Biol Chem. 1994; 269(40):24747-24755.
-
(1994)
J Biol Chem
, vol.269
, Issue.40
, pp. 24747-24755
-
-
Kim, H.H.1
Sierke, S.L.2
Koland, J.G.3
-
12
-
-
0028302018
-
ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor
-
SoltoffSP, Carraway KL, 3rd, Prigent SA, Gullick WG and Cantley LC. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol. 1994; 14(6):3550-3558.
-
(1994)
Mol Cell Biol
, vol.14
, Issue.6
, pp. 3550-3558
-
-
Soltoff, S.P.1
Carraway III, K.L.2
Prigent, S.A.3
Gullick, W.G.4
Cantley, L.C.5
-
13
-
-
2342591455
-
The discovery of receptor tyrosine kinases: targets for cancer therapy
-
Gschwind A, Fischer OM and Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004; 4(5):361-370.
-
(2004)
Nat Rev Cancer
, vol.4
, Issue.5
, pp. 361-370
-
-
Gschwind, A.1
Fischer, O.M.2
Ullrich, A.3
-
14
-
-
37049183697
-
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-182.
-
(1987)
Science
, vol.235
, Issue.4785
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
Levin, W.J.4
Ullrich, A.5
McGuire, W.L.6
-
15
-
-
3042622482
-
HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues
-
Owens MA, Horten BC and Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004; 5(1):63-69.
-
(2004)
Clin Breast Cancer
, vol.5
, Issue.1
, pp. 63-69
-
-
Owens, M.A.1
Horten, B.C.2
Da Silva, M.M.3
-
16
-
-
2142758687
-
HER-2 testing in breast cancer using parallel tissue-based methods
-
Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB and Gown AM. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004; 291(16):1972-1977.
-
(2004)
JAMA
, vol.291
, Issue.16
, pp. 1972-1977
-
-
Yaziji, H.1
Goldstein, L.C.2
Barry, T.S.3
Werling, R.4
Hwang, H.5
Ellis, G.K.6
Gralow, J.R.7
Livingston, R.B.8
Gown, A.M.9
-
17
-
-
84891633376
-
HER2-positive gastric cancer
-
Boku N. HER2-positive gastric cancer. Gastric Cancer. 2013.
-
(2013)
Gastric Cancer
-
-
Boku, N.1
-
18
-
-
84876437123
-
HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer
-
Chay WY, Chew SH, Ong WS, Busmanis I, Li X, Thung S, Ngo L, Lim SL, Lim YK, Chia YN, Koh E, Pang C, Soh LT, Wang J, Ho TH, Tay SK, et al. HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. PLoS One. 2013; 8(4):e61565.
-
(2013)
PLoS One
, vol.8
, Issue.4
-
-
Chay, W.Y.1
Chew, S.H.2
Ong, W.S.3
Busmanis, I.4
Li, X.5
Thung, S.6
Ngo, L.7
Lim, S.L.8
Lim, Y.K.9
Chia, Y.N.10
Koh, E.11
Pang, C.12
Soh, L.T.13
Wang, J.14
Ho, T.H.15
Tay, S.K.16
-
19
-
-
80052106168
-
Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas
-
Clauditz TS, ReiffM, Gravert L, Gnoss A, Tsourlakis MC, Munscher A, Sauter G, Bokemeyer C, Knecht R and Wilczak W. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas. Pathology. 2011; 43(5):459-464.
-
(2011)
Pathology
, vol.43
, Issue.5
, pp. 459-464
-
-
Clauditz, T.S.1
Reiff, M.2
Gravert, L.3
Gnoss, A.4
Tsourlakis, M.C.5
Munscher, A.6
Sauter, G.7
Bokemeyer, C.8
Knecht, R.9
Wilczak, W.10
-
20
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-792.
-
(2001)
N Engl J Med
, vol.344
, Issue.11
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
Fleming, T.7
Eiermann, W.8
Wolter, J.9
Pegram, M.10
Baselga, J.11
Norton, L.12
-
21
-
-
77956262693
-
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
-
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, RuschoffJ and Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-697.
-
(2010)
Lancet
, vol.376
, Issue.9742
, pp. 687-697
-
-
Bang, Y.J.1
Van Cutsem, E.2
Feyereislova, A.3
Chung, H.C.4
Shen, L.5
Sawaki, A.6
Lordick, F.7
Ohtsu, A.8
Omuro, Y.9
Satoh, T.10
Aprile, G.11
Kulikov, E.12
Hill, J.13
Lehle, M.14
Ruschoff, J.15
Kang, Y.K.16
-
22
-
-
33947637653
-
HER-2/neu overexpression is an independent prognostic factor in colorectal cancer
-
Park DI, Kang MS, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Han WK, Kim H, Ryu SH and Sepulveda AR. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis. 2007; 22(5):491-497.
-
(2007)
Int J Colorectal Dis
, vol.22
, Issue.5
, pp. 491-497
-
-
Park, D.I.1
Kang, M.S.2
Oh, S.J.3
Kim, H.J.4
Cho, Y.K.5
Sohn, C.I.6
Jeon, W.K.7
Kim, B.I.8
Han, W.K.9
Kim, H.10
Ryu, S.H.11
Sepulveda, A.R.12
-
23
-
-
61749084470
-
Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?
-
Kavanagh DO, Chambers G, O'Grady L, Barry KM, Waldron RP, Bennani F, Eustace PW and Tobbia I. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer. 2009; 9:1.
-
(2009)
BMC Cancer
, vol.9
, pp. 1
-
-
Kavanagh, D.O.1
Chambers, G.2
O'Grady, L.3
Barry, K.M.4
Waldron, R.P.5
Bennani, F.6
Eustace, P.W.7
Tobbia, I.8
-
24
-
-
10844274194
-
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial
-
Ramanathan RK, Hwang JJ, Zamboni WC, Sinicrope FA, Safran H, Wong MK, Earle M, Brufsky A, Evans T, Troetschel M, Walko C, Day R, Chen HX and Finkelstein S. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest. 2004; 22(6):858-865.
-
(2004)
Cancer Invest
, vol.22
, Issue.6
, pp. 858-865
-
-
Ramanathan, R.K.1
Hwang, J.J.2
Zamboni, W.C.3
Sinicrope, F.A.4
Safran, H.5
Wong, M.K.6
Earle, M.7
Brufsky, A.8
Evans, T.9
Troetschel, M.10
Walko, C.11
Day, R.12
Chen, H.X.13
Finkelstein, S.14
-
25
-
-
77957953603
-
Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers
-
Marx AH, Burandt EC, Choschzick M, Simon R, Yekebas E, KaifiJT, Mirlacher M, Atanackovic D, Bokemeyer C, Fiedler W, Terracciano L, Sauter G and Izbicki JR. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol. 2010; 41(11):1577-1585.
-
(2010)
Hum Pathol
, vol.41
, Issue.11
, pp. 1577-1585
-
-
Marx, A.H.1
Burandt, E.C.2
Choschzick, M.3
Simon, R.4
Yekebas, E.5
Kaifi, J.T.6
Mirlacher, M.7
Atanackovic, D.8
Bokemeyer, C.9
Fiedler, W.10
Terracciano, L.11
Sauter, G.12
Izbicki, J.R.13
-
26
-
-
49149118719
-
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
-
Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H and Wong KK. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008; 27(34):4702-4711.
-
(2008)
Oncogene
, vol.27
, Issue.34
, pp. 4702-4711
-
-
Li, D.1
Ambrogio, L.2
Shimamura, T.3
Kubo, S.4
Takahashi, M.5
Chirieac, L.R.6
Padera, R.F.7
Shapiro, G.I.8
Baum, A.9
Himmelsbach, F.10
Rettig, W.J.11
Meyerson, M.12
Solca, F.13
Greulich, H.14
Wong, K.K.15
-
27
-
-
33846566408
-
Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
-
Reid A, Vidal L, Shaw H and de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer. 2007; 43(3):481-489.
-
(2007)
Eur J Cancer
, vol.43
, Issue.3
, pp. 481-489
-
-
Reid, A.1
Vidal, L.2
Shaw, H.3
de Bono, J.4
-
28
-
-
84858002759
-
Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
-
De Greve J, Teugels E, Geers C, Decoster L, Galdermans D, De Mey J, Everaert H, Umelo I, In't Veld P and Schallier D. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer. 2012; 76(1):123-127.
-
(2012)
Lung Cancer
, vol.76
, Issue.1
, pp. 123-127
-
-
De Greve, J.1
Teugels, E.2
Geers, C.3
Decoster, L.4
Galdermans, D.5
De Mey, J.6
Everaert, H.7
Umelo, I.8
In't Veld, P.9
Schallier, D.10
-
29
-
-
36849067019
-
Nanocarriers as an emerging platform for cancer therapy
-
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R and Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007; 2(12):751-760.
-
(2007)
Nat Nanotechnol
, vol.2
, Issue.12
, pp. 751-760
-
-
Peer, D.1
Karp, J.M.2
Hong, S.3
Farokhzad, O.C.4
Margalit, R.5
Langer, R.6
-
30
-
-
14644439267
-
Cancer nanotechnology: opportunities and challenges
-
Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005; 5(3):161-171.
-
(2005)
Nat Rev Cancer
, vol.5
, Issue.3
, pp. 161-171
-
-
Ferrari, M.1
-
31
-
-
0034000453
-
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
-
Maeda H, Wu J, Sawa T, Matsumura Y and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-284.
-
(2000)
J Control Release
, vol.65
, Issue.1-2
, pp. 271-284
-
-
Maeda, H.1
Wu, J.2
Sawa, T.3
Matsumura, Y.4
Hori, K.5
-
32
-
-
84862819985
-
Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: synthesis, preparation and in vivo evaluation
-
Zhang P, Hu L, Yin Q, Zhang Z, Feng L and Li Y. Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: synthesis, preparation and in vivo evaluation. J Control Release. 2012; 159(3):429-434.
-
(2012)
J Control Release
, vol.159
, Issue.3
, pp. 429-434
-
-
Zhang, P.1
Hu, L.2
Yin, Q.3
Zhang, Z.4
Feng, L.5
Li, Y.6
-
33
-
-
84872914826
-
HER2 testing in breast cancer: an overview of current techniques and recent developments
-
Pathmanathan N and Bilous AM. HER2 testing in breast cancer: an overview of current techniques and recent developments. Pathology. 2012; 44(7):587-595.
-
(2012)
Pathology
, vol.44
, Issue.7
, pp. 587-595
-
-
Pathmanathan, N.1
Bilous, A.M.2
-
34
-
-
84863014544
-
Image analysis of HER2 immunohistochemical staining. Reproducibility and concordance with fluorescence in situ hybridization of a laboratory-validated scoring technique
-
Minot DM, Voss J, Rademacher S, Lwin T, Orsulak J, Caron B, Ketterling R, Nassar A, Chen B and Clayton A. Image analysis of HER2 immunohistochemical staining. Reproducibility and concordance with fluorescence in situ hybridization of a laboratory-validated scoring technique. Am J Clin Pathol. 2012; 137(2):270-276.
-
(2012)
Am J Clin Pathol
, vol.137
, Issue.2
, pp. 270-276
-
-
Minot, D.M.1
Voss, J.2
Rademacher, S.3
Lwin, T.4
Orsulak, J.5
Caron, B.6
Ketterling, R.7
Nassar, A.8
Chen, B.9
Clayton, A.10
-
35
-
-
84863715765
-
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
-
Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R and Hickish T. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat. 2012; 133(3):1057-1065.
-
(2012)
Breast Cancer Res Treat
, vol.133
, Issue.3
, pp. 1057-1065
-
-
Lin, N.U.1
Winer, E.P.2
Wheatley, D.3
Carey, L.A.4
Houston, S.5
Mendelson, D.6
Munster, P.7
Frakes, L.8
Kelly, S.9
Garcia, A.A.10
Cleator, S.11
Uttenreuther-Fischer, M.12
Jones, H.13
Wind, S.14
Vinisko, R.15
Hickish, T.16
-
36
-
-
84878663006
-
Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET
-
Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD, Gomes-DaGama EM, Chiosis G, Carbonetti G, de Stanchina E and Lewis JS. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. J Nucl Med. 2013; 54(6):936-943.
-
(2013)
J Nucl Med
, vol.54
, Issue.6
, pp. 936-943
-
-
Janjigian, Y.Y.1
Viola-Villegas, N.2
Holland, J.P.3
Divilov, V.4
Carlin, S.D.5
Gomes-DaGama, E.M.6
Chiosis, G.7
Carbonetti, G.8
de Stanchina, E.9
Lewis, J.S.10
-
38
-
-
84869757978
-
Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress
-
Cruickshanks N, Tang Y, Booth L, Hamed H, Grant S and Dent P. Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress. Mol Pharmacol. 2012; 82(6):1217-1229.
-
(2012)
Mol Pharmacol
, vol.82
, Issue.6
, pp. 1217-1229
-
-
Cruickshanks, N.1
Tang, Y.2
Booth, L.3
Hamed, H.4
Grant, S.5
Dent, P.6
-
39
-
-
77952866189
-
Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy
-
Blanco E, Bey EA, Khemtong C, Yang SG, Setti-Guthi J, Chen H, Kessinger CW, Carnevale KA, Bornmann WG, Boothman DA and Gao J. Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res. 2010; 70(10):3896-3904.
-
(2010)
Cancer Res
, vol.70
, Issue.10
, pp. 3896-3904
-
-
Blanco, E.1
Bey, E.A.2
Khemtong, C.3
Yang, S.G.4
Setti-Guthi, J.5
Chen, H.6
Kessinger, C.W.7
Carnevale, K.A.8
Bornmann, W.G.9
Boothman, D.A.10
Gao, J.11
-
40
-
-
39749178252
-
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
-
Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim SB, Rha SY, Lee MY and Ro J. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat. 2008; 108(2):241-250.
-
(2008)
Breast Cancer Res Treat
, vol.108
, Issue.2
, pp. 241-250
-
-
Lee, K.S.1
Chung, H.C.2
Im, S.A.3
Park, Y.H.4
Kim, C.S.5
Kim, S.B.6
Rha, S.Y.7
Lee, M.Y.8
Ro, J.9
-
41
-
-
79951682119
-
A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours
-
Plummer R, Wilson RH, Calvert H, Boddy AV, Griffin M, Sludden J, Tilby MJ, Eatock M, Pearson DG, Ottley CJ, Matsumura Y, Kataoka K and Nishiya T. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br J Cancer. 2011; 104(4):593-598.
-
(2011)
Br J Cancer
, vol.104
, Issue.4
, pp. 593-598
-
-
Plummer, R.1
Wilson, R.H.2
Calvert, H.3
Boddy, A.V.4
Griffin, M.5
Sludden, J.6
Tilby, M.J.7
Eatock, M.8
Pearson, D.G.9
Ottley, C.J.10
Matsumura, Y.11
Kataoka, K.12
Nishiya, T.13
-
42
-
-
10844293438
-
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
-
Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, Shirao K, Okusaka T, Ueno H, Ikeda M and Watanabe N. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer. 2004; 91(10):1775-1781.
-
(2004)
Br J Cancer
, vol.91
, Issue.10
, pp. 1775-1781
-
-
Matsumura, Y.1
Hamaguchi, T.2
Ura, T.3
Muro, K.4
Yamada, Y.5
Shimada, Y.6
Shirao, K.7
Okusaka, T.8
Ueno, H.9
Ikeda, M.10
Watanabe, N.11
-
43
-
-
77958073029
-
Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors
-
Hamaguchi T, Doi T, Eguchi-Nakajima T, Kato K, Yamada Y, Shimada Y, Fuse N, Ohtsu A, Matsumoto S, Takanashi M and Matsumura Y. Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin Cancer Res. 2010; 16(20):5058-5066.
-
(2010)
Clin Cancer Res
, vol.16
, Issue.20
, pp. 5058-5066
-
-
Hamaguchi, T.1
Doi, T.2
Eguchi-Nakajima, T.3
Kato, K.4
Yamada, Y.5
Shimada, Y.6
Fuse, N.7
Ohtsu, A.8
Matsumoto, S.9
Takanashi, M.10
Matsumura, Y.11
-
44
-
-
0029150245
-
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoffsize
-
Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP and Jain RK. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoffsize. Cancer Res. 1995; 55(17):3752-3756.
-
(1995)
Cancer Res
, vol.55
, Issue.17
, pp. 3752-3756
-
-
Yuan, F.1
Dellian, M.2
Fukumura, D.3
Leunig, M.4
Berk, D.A.5
Torchilin, V.P.6
Jain, R.K.7
-
45
-
-
84862517569
-
Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance
-
Zamboni WC, Torchilin V, Patri AK, Hrkach J, Stern S, Lee R, Nel A, Panaro NJ and Grodzinski P. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res. 2012; 18(12):3229-3241.
-
(2012)
Clin Cancer Res
, vol.18
, Issue.12
, pp. 3229-3241
-
-
Zamboni, W.C.1
Torchilin, V.2
Patri, A.K.3
Hrkach, J.4
Stern, S.5
Lee, R.6
Nel, A.7
Panaro, N.J.8
Grodzinski, P.9
-
46
-
-
51049092308
-
Factors affecting the clearance and biodistribution of polymeric nanoparticles
-
Alexis F, Pridgen E, Molnar LK and Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008; 5(4):505-515.
-
(2008)
Mol Pharm
, vol.5
, Issue.4
, pp. 505-515
-
-
Alexis, F.1
Pridgen, E.2
Molnar, L.K.3
Farokhzad, O.C.4
-
47
-
-
36148935211
-
Transport mechanisms of mmePEG750P(CL-co-TMC) polymeric micelles across the intestinal barrier
-
Mathot F, des Rieux A, Arien A, Schneider YJ, Brewster M and Preat V. Transport mechanisms of mmePEG750P(CL-co-TMC) polymeric micelles across the intestinal barrier. J Control Release. 2007; 124(3):134-143.
-
(2007)
J Control Release
, vol.124
, Issue.3
, pp. 134-143
-
-
Mathot, F.1
Des Rieux, A.2
Arien, A.3
Schneider, Y.J.4
Brewster, M.5
Preat, V.6
-
48
-
-
84862830732
-
Nanoparticle-based combination therapy toward overcoming drug resistance in cancer
-
Hu CM and Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol. 2012; 83(8):1104-1111.
-
(2012)
Biochem Pharmacol
, vol.83
, Issue.8
, pp. 1104-1111
-
-
Hu, C.M.1
Zhang, L.2
-
49
-
-
0032758610
-
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors
-
Drummond DC, Meyer O, Hong K, Kirpotin DB and Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999; 51(4):691-743.
-
(1999)
Pharmacol Rev
, vol.51
, Issue.4
, pp. 691-743
-
-
Drummond, D.C.1
Meyer, O.2
Hong, K.3
Kirpotin, D.B.4
Papahadjopoulos, D.5
-
50
-
-
84865363739
-
Targeting to overexpressed glucose-regulated protein 78 in gastric cancer discovered by 2D DIGE improves the diagnostic and therapeutic efficacy of micelles-mediated system
-
Cheng CC, Lu N, Peng CL, Chang CC, Mai FD, Chen LY, Liao MH, Wang WM and Chang J. Targeting to overexpressed glucose-regulated protein 78 in gastric cancer discovered by 2D DIGE improves the diagnostic and therapeutic efficacy of micelles-mediated system. Proteomics. 2012; 12(15-16):2584-2597.
-
(2012)
Proteomics
, vol.12
, Issue.15-16
, pp. 2584-2597
-
-
Cheng, C.C.1
Lu, N.2
Peng, C.L.3
Chang, C.C.4
Mai, F.D.5
Chen, L.Y.6
Liao, M.H.7
Wang, W.M.8
Chang, J.9
|